title: Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin.
abstract: The diaminocyclohexane platinum (Pt(DACH)) derivatives ormaplatin and oxaliplatin have caused severe and dose-limiting peripheral sensory neurotoxicity in a clinical trial. We hypothesized that this toxicity could vary in relation to the biotransformation and stereochemistry of these Pt(DACH) derivatives. We prepared pure R,R and S,S enantiomers of ormaplatin (Pt(DACH)Cl4), oxaliplatin (Pt(DACH)oxalato) and their metabolites (Pt(DACH)Cl2 and Pt(DACH)methionine) and assessed their peripheral sensory neurotoxicity and tissue distribution in the rat and in vitro anti-tumour activity in human ovarian carcinoma cell lines. The R,R enantiomers of Pt(DACH)Cl4, Pt(DACH)oxalato and Pt(DACH)Cl2, induced peripheral sensory neurotoxicity at significantly lower cumulative doses (18 +/- 5.7 vs 32 +/- 2.3 micromol kg(-1); P < 0.01) and at earlier times (4 +/- 1 vs 6.7 +/- 0.6 weeks; P = 0.016) during repeat-dose treatment than the S,S enantiomers. Pt(DACH)methionine enantiomers showed no biological activity. There was no difference between Pt(DACH) enantiomers in the platinum concentration in sciatic nerve, dorsal root ganglia, spinal cord, brain or blood at the end of each experiment. Three human ovarian carcinoma cell lines (41 M, 41 McisR and SKOV-3) showed no (or inconsistent) chiral discrimination in their sensitivity to Pt(DACH) enantiomers, whereas two cell lines (CH-1 and CH-1cisR) showed modest enantiomeric selectivity favouring the R,R isomer (more active). In conclusion, Pt(DACH) derivatives exhibit enantiomeric-selective peripheral sensory neurotoxicity during repeated dosing in rats favouring S,S isomers (less neurotoxic). They exhibited less chiral discrimination in their accumulation within peripheral nerves and in vitro anti-tumour activity.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, The University of Auckland School of Medicine, New Zealand.
authors.forename: D
authors.initials: D
authors.lastname: Screnci
authors.forename: H M
authors.initials: HM
authors.lastname: Er
authors.forename: T W
authors.initials: TW
authors.lastname: Hambley
authors.forename: P
authors.initials: P
authors.lastname: Galettis
authors.forename: W
authors.initials: W
authors.lastname: Brouwer
authors.forename: M J
authors.initials: MJ
authors.lastname: McKeage
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity*; D000077150:Oxaliplatin; D010525:Peripheral Nerves / Q000187:drug effects*; D010984:Platinum / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013237:Stereoisomerism
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010984:Platinum; C049777:ormaplatin